Evommune reported phase 2a results for EVO301, an IL‑18–binding long‑acting fusion protein, showing statistically significant improvement in Eczema Area and Severity Index (EASI) versus placebo. The company says the intravenously dosed molecule achieved competitive reductions in disease severity at week 12 and plans a phase 2b study testing a subcutaneous formulation and optimized dosing. Investors responded sharply: Evommune’s shares rallied on the readout as analysts flagged the 33% placebo‑adjusted EASI improvement as potentially competitive with established biologics. The company is positioning EVO301 as an alternative approach by neutralizing IL‑18, a distinct inflammatory axis; EASI is a validated clinician‑rated scale used to measure atopic dermatitis severity, with higher reductions indicating greater clinical benefit.